Akers Biosciences Announces a Change to the Board of Directors THOROFARE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces...

Akers Biosciences Withdraws FDA 510(k) Submission for PIFA Chlamydia Rapid Assay Pending Further Evaluation THOROFARE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces...

Akers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings THOROFARE, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, will...

Akers Biosciences Announces Conference Call to Discuss Its Third Quarter 2015 Earnings THOROFARE, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), (the "Company" or "Akers Bio"), a medical device company focused on reducing the cost of...

Akers Biosciences' Flagship Test for Heparin-Induced Thrombocytopenia Granted Approval by Chinese Food and Drug Administration THOROFARE, N.J., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare...